A. fumigatus also showed correlation with all other fungi (0.51-0.82, P < 0.05). The correlation between A. fumigatus and Asp f 2 was the strongest (r = 0.73, P < 0.01). The positivity rate and sIgE levels of Asp f 6 were significantly higher in patients with ABPA than in patients with AS (P < 0.05).
Methods: Eight severe asthmatic patients were received subcutaneous injection of benralizumab 30 mg per month. We assessed the asthma control (ACT, ACQ-5), asthma-related QOL (AQLQ), forced expiratory volume in one second (FEV1), symptom, exhaled nitric oxide (FeNO) level and reduction of systemic steroid use after one or two month-treatment of benralizumab.
Results: The mean age was 57.6 years, and the average duration of asthma was 33.8 years. The mean eosinophil count was 420.7 /microliter and the mean IgE level was 514.1 IU/ml. Half of the patients used oral corticosteroids (OCS) and 5 patients were treated with mepolizumab prior to benralizumab. The mean severe exacerbation rate was 3.8 per year under the GINA step 4 or 5 treatment. After one-month treatment, ACT score improved from 14.5 to 18.4, and ACQ-5 improved from 2.1 to 1.3 with complete depletion of peripheral eosinophils. AQLQ improved from 3.8 to 4.8 and 134 ml of FEV1 increased. FeNO level did not change. The reduction of OCS use was observed in two out of five patients. The comorbidity of eosinophilic sinusitis also improved in one patient.
Conclusion: Compared to mepolizumab, short term use of benralizumab improved asthma control, QOL, pulmonary function and reduced OCS use with complete elimination of peripheral eosinophils in Japanese patients with severe uncontrolled asthma. Background and Aims: Asthma education is crucial to prevent exacerbated symptoms and death. An Asthma Care Application (the app) was developed to provide self-care knowledge to reduce incidence of acute exacerbation of symptoms. The effectiveness, in terms of asthma knowledge and satisfaction among nurses, of the app was compared to traditional written directions for asthma prevention and treatment.
Methods: Nurses dealing in one Bangkok Metropolitan Area (BMA) hospital's asthma care attended an asthma knowledge workshop organized by the Center of Excellence for Allergy, Asthma and Pulmonary Diseases, Thammasat Hospital. They were randomly divided into two groups, one using the app and the other a written asthma action plan as educational instruments. Workshops were presented by lecturers on two consecutive days. Data about asthma knowledge and sample satisfaction was obtained by questionnaire before and after each group's workshop. Group scores were compared to determine effectiveness.
Results: Forty-four nurses were enrolled in the seminar; 25 (57%) used the app, half of them in emergency department. This group revealed a significant increase in post-test asthma knowledge scores compared to pre-test statistics (91%, 75% respectively; P = 0.002). By contrast, the written asthma action plan group showed less significant improvement in post-test scores (89%, 80% respectively; P = 0.135). The app group also reported higher satisfaction scores in terms of ease of asthma action plan usage, reducing the number of hospital admissions, with convenient access due to portability (P < 0.001, P = 0.026, P = 0.026 respectively).
Conclusion:
The app might be introduced to improve asthma knowledge and satisfaction among nurses in Thailand, compared to current written asthma action plans. More research on long-term benefits of the app with asthma patients would be indicated. Background and Aims: Asthma is a heterogeneous disorder presenting with many phenotypes, and recent interest is concentrated on the identification of phenotypes based on the pattern of inflammation in the airways and clinical symptoms. There are three types of asthma in our study, including cough variant asthma(CVA), cough predominant asthma (CPA) and classic asthma (CA). It is little known about the differences in clinical features and pathophysiology mechanisms of CVA, CPA and CA.
Methods: Asthmatic patients were enrolled and divided into CVA, CPA and NCPA. Questionnaires, spirometry, capsaicn cough challenge test, induced sputum test were performed in all patients. Cough severity was evaluated with VAS, symptom score and LCQ.
Results: A total of 461 patients with asthma were enrolled, with 111 CVA, 198 CPA and 152 CA. The prevalence of symptoms was as following: dyspnea (80.6%), wheeze (86.4%), cough (96.1%), chest tightness (56.4%). The major troublesome symptoms were dyspnea (43.6%), wheeze (41.9%), cough (60.4%), chest distress (7.8%). Compared with CA, patients with CPA had higher VAS score (P < 0.001) and lower LCQ score (P < 0.001). There were no significant differences in Eos% and Neu%, age, gender and combined diseases (AR, ST, GER and bronchiectasis) between CVA, CPA and CA. FEV1%pred, FEV1/FVC% and MMEF%pred were similar between CPA and CA. There was a higher trend of cough hypersensitivity in CPA patients as compared with CA (64% vs 36.4%, P = 0.059).Compared to the patients received standardized treatment(>3 months) and under controlled, patients received standardized treatment but without controlled had higher cough sensitivity and eosinophils in sputum (P < 0.05). 
Conclusion

